SCHEDULE: ADAR1 Capital Discloses 17.5% Stake in Rallybio

ADAR1 Capital Management and Daniel Schneeberger have reported a 17.5% beneficial ownership stake in Rallybio Corporation.

Summary

• ADAR1 Capital Management, LLC and Daniel Schneeberger have filed a Schedule 13G indicating a significant position in Rallybio Corporation.
• The reporting persons beneficially own 926,352 shares of common stock.
• This ownership represents 17.5% of the company's total outstanding common stock, based on 5,298,137 shares outstanding as of May 8, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it reflects strong institutional backing without the immediate volatility associated with activist intervention.

Positives

• The filing indicates a strong institutional interest in Rallybio Corporation with a substantial 17.5% stake.
• The acquisition is reported as being held in the ordinary course of business, suggesting a long-term investment perspective rather than an activist campaign.

Negatives

• The concentration of ownership in a single investment management firm may lead to increased stock volatility if the firm decides to divest its position.

Risks

• The investment is subject to market fluctuations and the general risks associated with the biotechnology sector.
• The reporting persons have certified that the shares were not acquired for the purpose of changing or influencing the control of the issuer, which limits their role in corporate governance.

Future Outlook

The reporting persons have stated that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control, implying a passive investment outlook.

Industry Context

StockSavvy.ai notes that significant 13G filings in the biotech sector often signal institutional confidence in a company's pipeline or valuation, though they can also precede M&A speculation.

Comparison to Industry Standards

• A 17.5% stake is a significant holding for an investment management firm, placing ADAR1 Capital among the top institutional shareholders for a company of Rallybio's market capitalization.
• The filing follows standard regulatory requirements for institutional investors exceeding the 5% ownership threshold.

Stakeholder Impact

• Shareholders may view the entry of a significant institutional investor as a validation of the company's long-term prospects.

Next Steps

• The reporting persons will be required to file amendments to this Schedule 13G if there are any material changes in the percentage of ownership.

Key Dates

Recommendation

The disclosure of a large institutional position is generally a positive signal, but as a passive investment, it does not fundamentally change the company's operational outlook, warranting a hold until further strategic developments occur.

Keywords

Rallybio, ADAR1 Capital, Schedule 13G, Institutional Ownership, Biotechnology, Common Stock